G1T28

Trilaciclib · G1 Therapeutics, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for G1T28, covering 2020-07-09 to 2020-07-09. Get the full timeline:

Most recent: Clinical Trial Update: Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC) [Phase 1, Phase 2]

See pricing